Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arecor Ltd.

www.arecor.com

Latest From Arecor Ltd.

Cipla Chief Calls For Invigorating Focus On Repurposed Drugs

Cipla chairman underscores the potential and value of repurposing drugs for Indian researchers and pharma firms looking to build their R&D activities, amid signs of growing attention to the promising area globally.
Research & Development India

Standing On The Shoulders Of Giants: Could Arecor Enter The Race To Revolutionize Diabetes?

A small Cambridge, UK-based company, which is more at home partnering with the pharma industry than competing with it, is readying its run into the diabetes space with its ultra-rapid acting insulin. Scrip talked to its CEO to about the company’s biggest year yet.

Strategy Clinical Trials

Start-Up Previews, February 2014

This Month's Profile Group, Strategic Spin-Outs: Biotech Start-Ups Structure Their Progeny For Success, features profiles of Envisia Therapeutics, f-star Alpha, Onkaido Therapeutics, Seragon Pharmaceuticals, and True North Therapeutics. Plus these Start-Ups Across Health Care: Arecor, Gecko Biomedical, and MediValve.

BioPharmaceutical Medical Device

Arecor Ltd.

Arecor Ltd.'s Arestat technology is designed to improve the stability of biologics that otherwise can't be formulated as a liquid, because they are too unstable or the required protein concentration means that the viscosity is too high. Arecor's platform allows its collaborators to develop new products, cut their development and manufacturing costs, or gain a competitive advantage by creating a ready-to-use formulation that can be given as a smaller or faster-acting dose.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Arecor Ltd.
  • Senior Management
  • Thomas R Saylor, CEO
    Tim Saxon, VP, Bus. Dev.
    Jan Jezek, PhD, CSO
  • Contact Info
  • Arecor Ltd.
    Phone: (44) 1223 426 060
    2 Cambridge Science Pk.
    Cambridge, CB4 0FE
    UK
UsernamePublicRestriction

Register